1. Home
  2. GOSS vs PFX Comparison

GOSS vs PFX Comparison

Compare GOSS & PFX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Gossamer Bio Inc.

GOSS

Gossamer Bio Inc.

HOLD

Current Price

$0.43

Market Cap

101.2M

Sector

Health Care

ML Signal

HOLD

PFX

PhenixFIN Corporation

HOLD

Current Price

$41.27

Market Cap

85.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
GOSS
PFX
Founded
2015
2010
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Finance: Consumer Services
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
101.2M
85.5M
IPO Year
2018
N/A

Fundamental Metrics

Financial Performance
Metric
GOSS
PFX
Price
$0.43
$41.27
Analyst Decision
Buy
Analyst Count
9
0
Target Price
$4.91
N/A
AVG Volume (30 Days)
25.1M
6.7K
Earning Date
03-17-2026
05-05-2026
Dividend Yield
N/A
3.46%
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$48,471,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$39.16
52 Week High
$3.87
$54.00

Technical Indicators

Market Signals
Indicator
GOSS
PFX
Relative Strength Index (RSI) 23.44 45.08
Support Level $0.33 N/A
Resistance Level $0.60 $45.62
Average True Range (ATR) 0.06 1.93
MACD 0.06 -0.13
Stochastic Oscillator 22.86 22.74

Price Performance

Historical Comparison
GOSS
PFX

About GOSS Gossamer Bio Inc.

Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.

About PFX PhenixFIN Corporation

PhenixFIN Corp is a non-diversified closed end management investment company operating in United States. Its investment objective is to generate current income and capital appreciation by lending directly to privately held middle market companies to expand their business, refinance and make acquisitions. It mainly invests in senior secured first lien term loans, senior secured second lien term loans, unitranche, senior secured first lien notes, subordinated notes and warrants and minority equity securities. It may also invest in securities of foreign companies. Portfolio of the company mainly consists of securities across all sectors. Revenue generated by the company comprises of interest income, dividend and other income earned through investments made.

Share on Social Networks: